<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4811">
  <stage>Registered</stage>
  <submitdate>29/01/2015</submitdate>
  <approvaldate>29/01/2015</approvaldate>
  <nctid>NCT02353897</nctid>
  <trial_identification>
    <studytitle>Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®</studytitle>
    <scientifictitle>An Assessment of Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®.</scientifictitle>
    <utrn />
    <trialacronym>APPEAL</trialacronym>
    <secondaryid>Y-79-52120-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Glabellar Lines</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess patient satisfaction regarding GL after three injection cycles of Dysport. - Assessed by patient auto questionnaire completion</outcome>
      <timepoint>Within 3 weeks ±7 days of visit 3</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To describe patient individual expectations. - Assessed by patient auto questionnaire completion</outcome>
      <timepoint>Within 3 weeks ±7 days of visit 1 and 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess patient satisfaction after one and two injection cycles of Dysport. - Assessed by patient auto questionnaire completion</outcome>
      <timepoint>Within 3 weeks ±7 days of visit 1 and 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To describe factors associated with patient satisfaction such as attractiveness, self-esteem, self-perceived age, desire to receive another injection. - Assessed by patient auto questionnaire completion</outcome>
      <timepoint>Within 3 weeks ±7 days of visit 1 and 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the GL severity (at rest and maximum frown) as per usual practice. - Physician assessment using GL severity scale</outcome>
      <timepoint>Baseline (visit 1) and visit 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess physician satisfaction after one and three injection cycles of Dysport. - 5 point Likert scale</outcome>
      <timepoint>Visit 1 follow up visit and visit 3 follow up visit (if performed)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To describe Dysport injection practices: muscles injected, total injected units, total volume injected, number of injection points and interval between injections.</outcome>
      <timepoint>From visit 1 until the end of the study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patient with moderate to severe GL naïve of any type of aesthetic
             treatment/procedure (invasive and non-invasive) for GL who provided written informed
             consent to take part.

          -  Patient who has prior to and independent of the study decided to undergo long term
             treatment of GL only (at least three cycles).

          -  Patient able to comply with the protocol (completion of web questionnaires).

          -  Patient whom physician intended to treat with Dysport independent of participation in
             the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient already included in this study.

          -  Participation in an interventional trial within 30 days prior to study entry.

          -  Patient who is at risk in terms of precautions, warnings, and contraindication (follow
             local Summary of Product Characteristics (SmPC) of Dysport).

          -  Female patient who is pregnant, nursing or planning a pregnancy during the study.

          -  Hypersensitivity to Dysport® or to its excipients.

          -  Presence of infection at the proposed injection sites.

          -  Presence of myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral
             sclerosis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>150</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>SouthDerm - Sydney</hospital>
    <hospital>ERASE - Victoria</hospital>
    <postcode>2217 - Sydney</postcode>
    <postcode>3144 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Botucatu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Kazakhstan</country>
      <state>Almaty</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Kocaeli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ipsen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to look at patient and physician satisfaction of long term Glabellar lines
      (GL) treatment with Dysport in a real life setting. It will also allow better understanding
      of what patients expect from the treatment, and the injection practices used by doctors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02353897</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ipsen Study Director</name>
      <address>Ipsen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>